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Protein-protein and protein nucleic acid interactions are vitally important for a wide range of 
biological processes, including regulation of gene expression, protein synthesis, and replication 
and assembly of many viruses. We have developed machine learning approaches for predicting 
which amino acids of a protein participate in its interactions with other proteins and/or nucleic 
acids, using only the protein sequence as input.  In this paper, we describe an application of 
classifiers trained on datasets of well-characterized protein-protein and protein-RNA 
complexes for which experimental structures are available. We apply these classifiers to the 
problem of predicting protein and RNA binding sites in the sequence of a clinically important 
protein for which the structure is not known: the regulatory protein Rev, essential for the 
replication of HIV-1 and other lentiviruses.  We compare our predictions with published 
biochemical, genetic and partial structural information for HIV-1 and EIAV Rev and with our 
own published experimental mapping of RNA binding sites in EIAV Rev. The predicted and 
experimentally determined binding sites are in very good agreement. The ability to predict 
reliably the residues of a protein that directly contribute to specific binding events - without the 
requirement for structural information regarding either the protein or complexes in which it 
participates - can potentially generate new disease intervention strategies.   
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1. Introduction   
The human AIDS virus, Human immunodeficiency virus Type 1 (HIV-1), is 
closely related to a number of lentiviruses that cause persistent, insidious 
infections in other primates and domestic animals. Recent advances in molecular 
virology have resulted in novel antiviral therapies that inhibit specific proteins 
required for the replication of lentiviruses and other important retroviruses. Rev 
is a multifunctional regulatory protein that plays an essential role in the 
production of infectious virus (1, 2) and, as such, is an attractive target for new 
antiviral therapies. To date, however, no Rev-targeted drugs for AIDS therapy 
are available. 
Rev is known to participate in protein-protein interactions with several 
cellular proteins as well as in RNA-protein interactions with lentiviral RNAs (3, 
4). It is required for the transition to the late stage of viral replication and 
facilitates export of incompletely spliced viral RNAs from the nucleus to the 
cytoplasm. After its import into the nucleus, HIV-1 Rev binds a structure in the 
viral pre-mRNA called the Rev-responsive element (RRE) (5, 6), multimerizes 
(6, 7), then utilizes the CRM1 nuclear export pathway to redirect movement of 
incompletely spliced viral RNA out of the nucleus (8). As shown in Figure 1, 
functional domains within HIV-1 Rev are known to mediate interactions with 
viral RNA and with host cell proteins that are required for nuclear localization, 
RNA binding, multimerization, and nuclear export (3). 
Efforts to develop inhibitors of Rev activity have been hampered by a lack 
of information regarding Rev protein structure. A major stumbling block for 
structural analysis is the tendency of Rev to aggregate at concentrations needed 
for crystallization or solution NMR studies (9). The only high resolution 
information available is for short peptide fragments of HIV-1 Rev. In an NMR 
solution structure of a 23 amino acid fragment of Rev bound to a 34 nucleotide 
RRE RNA fragment, the Rev peptide adopts an α-helical conformation and is 
bound in the major groove of the RNA (10). Structures of other critical 
functional domains of Rev (e.g., nuclear localization, multimerization, export) 
have not been reported. Furthermore, it has not been possible to apply homology 
modeling approaches to gain insight into Rev structure because Rev has no 
detectable sequence similarity to any protein of known structure.  Indeed, 
despite their apparently conserved functions, Rev protein sequences are highly 
variable between species, with < 10% sequence identity between HIV-1 and one 
 
 
 
 
 
 
of the most divergent Rev proteins, equine infectious anemia virus, (EIAV) Rev 
(11).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Functional domains of HIV-1 and EIAV Rev proteins.  The linear 
organization of functional domains within the two Rev proteins differs 
significantly, but both have been shown to contain specific sequences involved 
in Rev interactions with proteins (MUL, NLS, NES) or RNA (RBD, ARMs). 
 
 
When protein structures cannot be solved using experimental approaches, 
computational analyses can provide valuable insight into protein structure-
function relationships and aid in identification of key functional residues that 
may offer tractable targets for therapeutic intervention in disease (12).  Here we 
describe the identification of critical residues that mediate protein-protein and 
protein-RNA interactions in Rev, using machine learning approaches that rely 
on the primary amino acid sequence of Rev, but do not require any information 
regarding its structure or the sequence or structure of its interaction partners. 
Our predictions are in good agreement with previously published biochemical, 
 
 
 
 
 
 
biophysical and genetic data for HIV-1 and EIAV Rev as well as with our recent 
experimental mapping of RNA binding sites in EIAV Rev (13). Taken together, 
these results demonstrate the utility of sequence-based approaches for 
identifying putative binding sites of proteins with potential therapeutic value that 
are, at present, recalcitrant to experimental structure determination. 
2. Datasets, Materials and Methods  
2.1. Datasets  
Protein-protein binding site dataset  (PBS). We extracted individual proteins 
from a set of 70 protein–protein heterocomplexes used in the study of 
Chakrabarti and Janin (14). After removal of redundant proteins and molecules 
with fewer than 10 residues, we obtained a dataset of 77 individual proteins with 
sequence identity <30%.  The dataset contains a total of 12,719 amino acids, of 
which 2340 (18.4%) are interface residues (positive examples). 
 
RNA-protein binding dataset  (RBS). A dataset of protein-RNA interactions 
was extracted from structures of known protein-RNA complexes in the Protein 
Data Bank (PDB) (15).  Proteins with >30% sequence identity or structures with 
resolution worse than 3.5Å were removed using PISCES (16).  This resulted in a 
set of 109 non-redundant protein chains containing a total of 25,118 amino 
acids. Amino acids in the protein-RNA interface were identified using 
ENTANGLE (17). Using default parameters, 3518 (14%) of the amino acids in 
the dataset are defined as interface residues (positive examples). 
2.2. Protein-protein interface residue prediction 
We have previously developed a two-stage classifier for predicting interface 
residues in protein-protein complexes (18). In the first stage, a Support Vector 
Machine (SVM), trained on the PBS dataset, is used to classify each residue as 
interface or non-interface. Input to the SVM is a window of nine amino acid 
identities. Because interface residues tend to be clustered in primary sequence, a 
second stage was introduced to take advantage of this to improve predictions. In 
the second stage, a Bayesian Network classifier is trained based on the 
predictions of the target residue and its neighbors from the first stage SVM. Let 
C ∈ {0,1} denote the actual class label of a residue; X ∈ {0,1} be the prediction 
of the SVM classifier; Y denote the number of predicted interface residues 
 
 
 
 
 
 
within 4 amino acids of the target residue. For each residue, the likelihood that it 
is an interface residue given the SVM predictions for itself and its neighbors is 
calculated and compared to a chosen threshold θ as formula 1. 
                      (1) 
 
The residue is predicted to be an interface residue if the likelihood is larger 
than θ and non-interface otherwise. The conditional probability table P(C|X,Y) 
is derived from training datasets. To determine θ, the classifier was applied to 
the training set and different values of θ ranging from 0.01 to 1 were tested, in 
increments of 0.01. The value of θ for which the classifier yields the highest 
correlation coefficient was used to make predictions on the Rev proteins. 
2.3. Protein-RNA interface residue prediction 
We have previously developed a Naïve Bayes (NB) classifier for predicting 
which amino acids in a given protein are likely to be found in protein-RNA 
interfaces (19), using the NB classifier from the Weka package (20). The input 
is a window of 25 contiguous amino acid identities. The output is an instance 
where + indicates that the target residue is an interface residue and – indicates a 
non-interface residue. A training example is an ordered pair (x, c) where ( )nnTTTnn xxxxxxxx ,,...,,.,.., 1111 −+−+−−=  and c is the corresponding class label 
(interface or non-interface).  A training data set D is a collection of labeled 
training examples.  
Let ( )nTn XXXX ,...,...−=  denote the random variable corresponding to the 
input to the classifier and C denote the binary random variable corresponding to 
the output of the classifier. The Naïve Bayes classifier assigns input x the class 
label + (interface) if:  
 
 
 
 
and the class label – (non interface) otherwise.  θ  was set to the value that 
optimized the correlation coefficient (21) on the training set in each leave-one-
out cross validation experiment.  
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2.4.  Experimental mapping of RNA binding sites  
Details of our experimental mapping of RNA binding sites are provided in 
Lee et al., (13). Briefly, Maltose Binding Protein-EIAV Rev (MBP-ERev) 
constructs containing deletions or point mutations in the EAIV Rev coding 
region were cloned in pHMTc, based on the pMal-c2x expression vector, which 
enhances solubility of Rev fusion proteins. MBP-ERev fusion proteins were 
expressed in E. coli, purified prior to use in RNA binding experiments. UV cross 
linking experiments were used to quantitate the effects of mutations on Rev 
RNA binding activity (13). 
3. Results   
3.1. Binding site predictions on datasets of known protein-protein and 
protein-RNA complexes 
In previous work, we have developed classifiers for predicting interface residues 
in protein-protein, protein-DNA and protein RNA complexes (18, 19, 22), 
typically using a combination of sequence and structure-derived information as 
input. In choosing classifiers for the task of predicting protein-protein and 
protein-RNA interface residues in Rev proteins, we compared several types of 
classifiers for predicting each type of interface residue (data not shown). Table 1 
shows an example of the classification performance values obtained for protein 
binding site prediction using the PBS dataset, which contains 77 proteins used in 
our previous study (18) and for RNA binding site prediction using the RBS 
dataset, which contains 109 RNA-binding proteins (19).  
 
 
Table 1. Classification performance in predicting protein-protein and RNA-
protein binding site residues, using leave-one-out experiments  
 
Classification Performance 
Measure 
Protein Interface 
Residues 
(2-stage classifier) 
RNA Interface 
Residues 
(NB classifier) 
Accuracy  72% 85% 
Specificity 58% 51% 
Sensitivity 39% 38% 
Correlation coefficient 0.30 0.35 
 
 
 
 
 
 
These results were obtained using a modified 2-stage classifier developed in this 
work to predict protein interface residues (see Methods) and a Naive Bayes 
classifier published previously (19) to predict RNA interface residues. The 
results of the latter study are reproduced here for comparison. 
3.2. Predicted binding sites in wildtype HIV-1 and EIAV Rev proteins  
Using classifiers trained on the datasets described above, we predicted protein-
protein and protein-RNA interface residues in Rev proteins from HIV-1 and 
EIAV. As shown in Figure 2A, the 2-stage protein classifier predicted a total of 
56 protein-protein interface residues (indicated by "p") within the 116 amino 
acid HIV-1 Rev sequence. These are primarily located in 5 clusters consisting of 
6-15 amino acids. The Naive Bayes classifier predicted a total of 26 RNA-
protein interface residues (indicated by "r"), located in a single large cluster 
near the N-terminus of the protein. The predicted RNA binding site sequence is 
PPNPEGTRQARRNRRRRWRERQRQIHSIG, corresponding to amino acids 
28-56.  Ile26 and Ile29 are the only two residues within this sequence that are 
predicted to be non-interface residues.   
The prediction results for EIAV Rev, using the same classifiers, are shown 
in Figure 2B. A total of 79 protein-protein interface residues were predicted in 
the 165 amino acid protein. In EIAV Rev, most of these predicted protein-
binding residues are also located in 5 clusters that are somewhat larger (8-24 
amino acids) than those predicted in HIV-1. There are two predicted clusters of 
RNA-protein interface residues, one consisting of 15 contiguous amino acids, 
located in the central region and a second consisting of 19 contiguous residues at 
the C-terminus of the protein. The predicted RNA binding site sequences are 
RHLGPGPTQHTPSRR, (aa 63-77) and QSSPRVLRPGDSKRRRKHL (aa 147-
165. The only other predicted interface residues are 5 scattered amino acids in 
the region of aa 113-133.    
3.3. Comparison of predicted Rev binding sites with experimental data 
Functional domains in HIV-1 Rev have been extensively interrogated 
through the analysis of sequence variants and mutants generated both in vivo and 
in vitro (4). These experimental results are summarized in Figure 1 and mapped 
onto amino acid sequence of HIV-1 Rev for comparison with our predicted 
RNA and protein interface residues in Figure 2A. Notably, the single cluster of 
 
 
 
 
 
 
RNA interface residues predicted by the Naive Bayes classifier closely matches 
the experimentally mapped RNA binding domain (RBD), which in HIV-1 also 
includes an Arginine Rich Motif (ARM) that also functions as a nuclear 
localization signal (NLS).  Three predicted clusters of protein interface residues 
also characterized protein binding sites: one cluster (aa 22-32) maps to Rev 
multimerization domain, and two clusters are located within a large C-terminal 
domain (aa 87-116) that has been shown to play multiple roles in nuclear export, 
dimerization and transactivation activities of HIV-1 Rev (23). One of these 
clusters (aa75-93) also overlaps with the modular nuclear export signal (NES), 
which is interchangeable between various lentiviruses, including HIV-1 and 
EIAV (24). 
Although the functional domains in EIAV Rev have been studied in less 
detail than those in HIV-1 Rev, previous biochemical and genetic studies had 
localized the NLS and NES domains and implicated two motifs in the central 
region in RNA binding, RRDRW and ERLE (Figure 1) (13, 25-28). In 
predictions generated before we initiated our experimental mapping of EIAV 
RNA-binding domains, the Naïve Bayes classifier identified one potential RNA-
binding region overlapping the RRDRW motif and another overlapping a 
KRRRK motif within the mapped C-terminal NLS domain, but did not predict 
any interface residues near the ERLE motif. Our recent direct mapping of the 
RNA binding domain of EIAV Rev by UV cross linking showed that two 
separate regions of Rev are necessary for RNA binding: a central region 
encompassing aa 75-127 and a region comprising the 20 C-terminal residues of 
EIAV Rev (13). These experiments also demonstrated critical roles for both the 
central RRDRW motif and the KRRRK motif within the NLS in RNA-binding 
(13). Interestingly, however, the ERLE motif was not required for RNA-binding, 
in agreement with our predictions. Thus, our biochemical RNA-binding site 
mapping studies for EIAV Rev have provided direct experimental validation of 
the RNA interface residue predictions of the Naive Bayes classifier. 
Of the five clusters of predicted protein binding residues in EIAV Rev, two 
overlap with known or putative protein interaction domains (the NES and the 
NLS, respectively), one is located in the non-essential "hypervariable" region 
(13), one is located near the N-terminus of the protein, and one overlaps within 
the central RNA binding domain (Figure 3B).  There is no available biochemical 
data regarding the possibility that the central region of EIAV Rev binds both 
RNA and protein, but it is interesting that the classifier predicted binding of the 
 
 
 
 
 
 
NLS region to both protein and RNA. The same residues could directly interact 
with both the nuclear import machinery and RNA because these interactions 
occur at different times and in different cellular compartments.  Also, by 
analogy with HIV-1 Rev, it is likely that some of the protein interactions that 
occur when EIAV Rev multimerizes after binding RNA involve additional 
residues located near the RNA binding region that initiates the specific 
interaction between Rev and the RRE in unspliced EIAV RNA.  
 
 
A. 
 1.........11........21........31........41........51........ 
SEQ MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERIL 
PRO ....pppppppp.........ppppppppppp...........................p 
RNA ...r.........................r.rrrrrrrrrrrrrrrrrrrr.rr.r.r.. 
 
61........71........81........91........101.......111... 
SEQ GTYLGRSAEPVPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE 
PRO .pppppppppp.....p..pppppppppppppp.pp..ppp.........pppppp 
RNA ........................................................ 
 
 
B. 
1.........11........21........31........41........51........ 
SEQ MAESKEARDQEMNLKEESKEEKRRNDWWKIDPQGPLESDQWCRVLRQSLPEEKISSQTCI 
PRO .....pppppppp..........ppppppppppppppppppp.....pp........... 
RNA ............................................................ 
 
61........71........81........91........101.......111....... 
SEQ ARRHLGPGPTQHTPSRRDRWIREQILQAEVLQERLEWRIRGVQQVAKELGEVNRGIWREL 
PRO ppppppppppppppp....................................ppppppppp 
RNA ..rrrrrrrrrrrrrrr....................................r...... 
 
121.......131.......141.......151.......161.. 
SEQ HFREDQRGDFSAWGDYQQAQERRWGEQSSPRVLRPGDSKRRRKHL 
PRO ppppppppppppppp.............pp...ppp...pppppp 
RNA ............r.............rrrrrrrrrrrrrrrrrrr 
 
Figure 2.  Predicted interface residues in Rev proteins. The protein sequences 
(SEQ) for A) HIV-1 Rev & B) EIAV Rev are shown on top line, with binding 
site residues for protein (PRO) and RNA shown by "p" or "r" on the lines below. 
Important functional domains boxed in the sequence are:  NES, NLS/ARM ,RBD,  
MULTIMERIZATION, MULTIFUNCTIONAL, ARM, UNKNOWN. 
 
 
 
 
 
 
 
 
3.4. Comparison of predicted and biochemically mapped RNA binding 
sites in EIAV mutant Rev proteins 
Site-specific mutagenesis, coupled with functional assays, has identified 
functional domains of EIAV Rev (13, 25, 26). As mentioned above, an 
NLS/ARM at the C-terminus was identified at the EIAV Rev C-terminus and 
our cross-linking analyses of the RRDRW and KRRRK motifs indicated that 
both are likely to contact RNA. To investigate whether our classifiers are 
capable of detecting mutations that give rise to differences in RNA binding, we 
performed predictions on several mutant EIAV Rev sequences. As shown in 
Figure 3, changes in RNA interface predictions are seen in sequences in which 
Ala residues are substituted for positively charged residues in the RRDRW and 
KRRRK motifs (to AADAA and KAAAK). These mutations result in >80% 
reduction in RNA binding activity (13). The predicted RNA binding sites no 
longer overlap these motifs. In contrast, predicted protein interface residues 
remain unchanged, consistent with the experimental results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. RNA binding site predictions differ for "wildtype" and mutant EIAV 
Rev sequences. Predicted protein (PRO) and RNA binding sites are indicated 
along the sequence (SEQ). A. Wildtype, B. & C. Mutant EIAV Rev sequences. 
RNA binding activity is reduced by >80% in both mutants (see text for details). 
 
4. Summary and Discussion 
Many effective antiviral drugs are directed at blocking the interaction 
between regulatory proteins and their binding partners or small effector ligands. 
HIV-1 Rev is one of several clinically important proteins that are 
 
 
 
 
 
 
"experimentally recalcitrant," i.e., for which it has not been possible to obtain 
high resolution structural information. Identifying critical functional residues in 
Rev is further complicated by the fact that Rev proteins have no significant 
sequence similarity to any protein with known structure, and that Rev sequences 
from different species have very little similarity to one another. 
Our comparison of predictions with experimental data on the Rev proteins 
from HIV-1 and EIAV demonstrates that sequence-based computational 
methods can identify residues in "recalcitrant" proteins that interact with other 
proteins or nucleic acids. When structural information is available for a protein 
of interest, enhanced prediction accuracy can be achieved (18, 29). Developing 
improved methods for predicting binding sites will contribute to our 
understanding of how proteins recognize their targets in cells and may 
significantly decrease the time needed to precisely map binding sites in the 
laboratory. The level of accuracy obtained using the sequence-based methods 
presented here suggests that they could expedite the design of experiments to 
explore the function of key regulatory proteins, even when no structural 
information is available, with obvious implications for developing new therapies 
for both genetic and infectious diseases.  
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